Cargando…

New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging

Cardio-oncology requires a good knowledge of the cardiotoxicity of anticancer drugs, their mechanisms, and their diagnosis for better management. Anthracyclines, anti-vascular endothelial growth factor (VEGF), alkylating agents, antimetabolites, anti-human epidermal growth factor receptor (HER), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadour, Farah, Thuny, Franck, Sourdon, Joevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858802/
https://www.ncbi.nlm.nih.gov/pubmed/35198613
http://dx.doi.org/10.3389/fcvm.2022.813883
_version_ 1784654315145658368
author Cadour, Farah
Thuny, Franck
Sourdon, Joevin
author_facet Cadour, Farah
Thuny, Franck
Sourdon, Joevin
author_sort Cadour, Farah
collection PubMed
description Cardio-oncology requires a good knowledge of the cardiotoxicity of anticancer drugs, their mechanisms, and their diagnosis for better management. Anthracyclines, anti-vascular endothelial growth factor (VEGF), alkylating agents, antimetabolites, anti-human epidermal growth factor receptor (HER), and receptor tyrosine kinase inhibitors (RTKi) are therapeutics whose cardiotoxicity involves several mechanisms at the cellular and subcellular levels. Current guidelines for anticancer drugs cardiotoxicity are essentially based on monitoring left ventricle ejection fraction (LVEF). However, knowledge of microvascular and metabolic dysfunction allows for better imaging assessment before overt LVEF impairment. Early detection of anticancer drug-related cardiotoxicity would therefore advance the prevention and patient care. In this review, we provide a comprehensive overview of the cardiotoxic effects of anticancer drugs and describe myocardial perfusion, metabolic, and mitochondrial function imaging approaches to detect them before over LVEF impairment.
format Online
Article
Text
id pubmed-8858802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88588022022-02-22 New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging Cadour, Farah Thuny, Franck Sourdon, Joevin Front Cardiovasc Med Cardiovascular Medicine Cardio-oncology requires a good knowledge of the cardiotoxicity of anticancer drugs, their mechanisms, and their diagnosis for better management. Anthracyclines, anti-vascular endothelial growth factor (VEGF), alkylating agents, antimetabolites, anti-human epidermal growth factor receptor (HER), and receptor tyrosine kinase inhibitors (RTKi) are therapeutics whose cardiotoxicity involves several mechanisms at the cellular and subcellular levels. Current guidelines for anticancer drugs cardiotoxicity are essentially based on monitoring left ventricle ejection fraction (LVEF). However, knowledge of microvascular and metabolic dysfunction allows for better imaging assessment before overt LVEF impairment. Early detection of anticancer drug-related cardiotoxicity would therefore advance the prevention and patient care. In this review, we provide a comprehensive overview of the cardiotoxic effects of anticancer drugs and describe myocardial perfusion, metabolic, and mitochondrial function imaging approaches to detect them before over LVEF impairment. Frontiers Media S.A. 2022-02-07 /pmc/articles/PMC8858802/ /pubmed/35198613 http://dx.doi.org/10.3389/fcvm.2022.813883 Text en Copyright © 2022 Cadour, Thuny and Sourdon. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Cadour, Farah
Thuny, Franck
Sourdon, Joevin
New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging
title New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging
title_full New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging
title_fullStr New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging
title_full_unstemmed New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging
title_short New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging
title_sort new insights in early detection of anticancer drug-related cardiotoxicity using perfusion and metabolic imaging
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8858802/
https://www.ncbi.nlm.nih.gov/pubmed/35198613
http://dx.doi.org/10.3389/fcvm.2022.813883
work_keys_str_mv AT cadourfarah newinsightsinearlydetectionofanticancerdrugrelatedcardiotoxicityusingperfusionandmetabolicimaging
AT thunyfranck newinsightsinearlydetectionofanticancerdrugrelatedcardiotoxicityusingperfusionandmetabolicimaging
AT sourdonjoevin newinsightsinearlydetectionofanticancerdrugrelatedcardiotoxicityusingperfusionandmetabolicimaging